Selected article for: "angiotensin receptor and disease course"
Author: Miedema, Jelle; Schreurs, Marco; van der Sar – van der Brugge, Simone; Paats, Marthe; Baart, Sara; Bakker, Marleen; Hoek, Rogier; Dik, Willem Arnout; Endeman, Henrik; Van Der Velden, Vincent; van Gammeren, Adriaan; Ermens, Antonius; Aerts, Joachim G.; Thüsen, Jan Von Der
Title: Antibodies Against Angiotensin II Receptor Type 1 and Endothelin A Receptor Are Associated With an Unfavorable COVID19 Disease Course
  • Cord-id: gazjip1j
  • Document date: 2021_5_13
    • ID: gazjip1j
    Snippet: BACKGROUND: Lung histopathology demonstrates vasculopathy in a subset of deceased COVID19 patients, which resembles histopathology observed in antibody-mediated lung transplant rejection. Autoantibodies against angiotensin II type 1 receptor (AT1R) and Endothelin receptor Type A (ETAR) have been demonstrated in antibody-mediated rejection and may also be associated with severe COVID19 infection. Objective To assess AT1R and ETAR auto-antibodies in COVID19 patients and controls, and explore their
    Document: BACKGROUND: Lung histopathology demonstrates vasculopathy in a subset of deceased COVID19 patients, which resembles histopathology observed in antibody-mediated lung transplant rejection. Autoantibodies against angiotensin II type 1 receptor (AT1R) and Endothelin receptor Type A (ETAR) have been demonstrated in antibody-mediated rejection and may also be associated with severe COVID19 infection. Objective To assess AT1R and ETAR auto-antibodies in COVID19 patients and controls, and explore their association with disease course. METHODS: 65 hospitalized patients with COVID19 infection were included. Clinical and laboratory findings were retrospectively assessed. Patients with unfavorable disease course, admitted at the intensive care unit and/or deceased during hospital admission (n=33) were compared to admitted COVID19 patients with favorable disease course (n=32). The presence of antinuclear antibodies (ANA) and auto-antibodies against AT1R or ETAR in peripheral blood were compared between COVID19 with unfavorable and favorable disease course and age matched controls (n=20). RESULTS: The presence of ANA was not significantly different between COVID19 patients with unfavorable (n=7/33; 21%) and favorable disease course (n=6/32; 19%) (p= 0.804) and controls (n=3/20; 15%). Auto-antibodies against AT1R were significantly increased in unfavorable disease course (median 14.59 U/mL, IQR 11.28 – 19.89) compared to favorable disease course (median 10.67 U/mL, IQR 8.55 – 13.0, p< 0.01). ETAR antibody titers were also significantly increased in unfavorable disease course (median 7.21, IQR 5.0 – 10.45) as compared to favorable disease course (median 4.0, IQR 3.0 – 6.0, p <0.05). CONCLUSION: Auto-antibodies against AT1R and ETAR are significantly increased in COVID19 patients with an unfavorable disease course.

    Search related documents:
    Co phrase search for related documents
    • ace inhibitor and acute pneumonia respiratory distress syndrome: 1
    • ace inhibitor and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • ace inhibitor therapy and acute pneumonia: 1
    • ace inhibitor therapy and acute pneumonia respiratory distress syndrome: 1
    • ace inhibitor therapy and acute respiratory: 1, 2, 3, 4, 5
    • acute pneumonia and lung histopathology: 1, 2, 3, 4
    • acute pneumonia and lung transplant: 1, 2, 3, 4, 5, 6, 7
    • acute pneumonia and lung transplantation: 1, 2, 3, 4, 5, 6, 7, 8
    • acute pneumonia respiratory distress syndrome and lung transplant: 1
    • acute pneumonia respiratory distress syndrome and lung transplantation: 1, 2
    • acute respiratory and local treatment protocol: 1, 2
    • acute respiratory and lung histopathology: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • acute respiratory and lung transplant: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and lung transplant rejection: 1, 2
    • acute respiratory and lung transplantation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25